Clinical trial · Interventional
The Effect of Dihydroartemisinin in PCOS
The Evaluation of the Effect of Dihydroartemisinin in Patients With Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Artemisinin has been widely used as a first-line antimalarial drug in routine clinical practice. In recent years, it has been reported that Artemisinin also has some significant anti-inflammatory, anti-tumor and immune-modulating effects. The investigators' previous studies discovered that Artemisinin dramatically reduced serum androgen levels and improved poly-cystic ovary syndrome(PCOS) in animals. Preliminary study by the investigators found that artemisinin derivatives are capable of reducing both androgen levels and improving insulin resistance, two clinical characteristics of PCOS. Thus artemisinin derivatives has the potential effect to alleviate PCOS symptoms. The current study aims to investigate the effect of artemisinin on improving PCOS and serum androgen levels in PCOS subjects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dihydroartemisinin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dihydroartemisinin Group
- description
- The subjects take Dihydroartemisinin, 40mg tid for 12 weeks
- interventionNames
- Drug: Dihydroartemisinin
Primary outcomes (4)
- measure
- Recovery of regular menses by questionnaire
- timeFrame
- 12 weeks
- description
- Periodical vaginal bleeding by questionnaire
- measure
- Bilateral ovary volume
- timeFrame
- 12 weeks
- description
- Length, width and height of bilateral ovaries measured by B type ultrasound
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 16 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * BMI 23-30kg/M2 * No plan for pregnancy in the coming 6 months * Newly diagnosed PCOS, or PCOS without any medication for the past three months. * Patients should meet all the three following criteria: 1. Oligomenorrhea or amenorrhea: Oligomenorrhea is defined as more than 35 days between menstrual periods and less than 8 menstrual bleedings in the past year; amenorrhea is defined as more than 90 days between two menstrual bleedings. 2. Polycystic ovaries: ≥12 follicles in both ovaries (diameter\<10mm), confirmed by ultrasound. 3. Elevated androgen levels: testosterone\>1.67 nmol/L. Exclusion Criteria: * Previously treated with steroids or other medications for PCOS in the past 3 months. * Patients with other endocrine diseases that can cause secondary PCOS, including but not limited to: 21 hydroxylase deficiency, prolactinoma, hypothyroidism, Cushing's syndrome, etc. * Pregnancy. * Patients with other serious diseases affecting heart, liver, kidney, or other major organs. * Patients with any type of cancer.
References
Publications (0)
Data not yet available